Register Login

Heron Therapeuti (HRTX)

(19% Negative) Heron Therapeutics, Inc. (HRTX) Announces Delay in portfolio Development Timeline Due to Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 6:15 p.m.

    📋 Heron Therapeutics, Inc. (HRTX) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 13:08:24

    Event Type: Clinical Trial Update

    Event Details:

    Heron Therapeuti (HRTX) Announces Clinical Trial Update Heron Therapeuti (HRTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: portfolio, growth
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Regulatory Process
    • Collaboration: Heron Therapeutics, Inc.
    • Updated Timeline: full-year 2025, Full-Year 2025

    🔬 Clinical Development Pipeline (Heron Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    Vehicle BIOLOGICAL Phase PHASE2 Glabellar Lines ClinicalTrials.gov
    AI-09 Ready Use Injectable Botulinum Toxin BIOLOGICAL Phase PHASE2 Glabellar Lines ClinicalTrials.gov
    Placebo control / saline vehicle OTHER Phase PHASE3 Knee Osteoarthritis ClinicalTrials.gov
    PTP-01 BIOLOGICAL Phase PHASE3 Knee Osteoarthritis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Heron Therapeuti
    • CIK: 0000818033
    • Ticker Symbol: HRTX
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories